Abstract: The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.

Abstract: Aspects of the application relate to methods and compositions for delivering therapeutic nucleic acids to neural cells or tissue in a subject. Additional aspects of the application relate to therapeutic nucleic acids, for example therapeutic ribozymes, that are useful for inhibiting viral reactivation in a subject.

Abstract: The present disclosure provides for base editors which satisfy a need in the art for installation of targeted transversions of thymine (T) to adenine (A), or correspondingly, trans versions of adenine (A) to thymine (T). The nucleobase editor domains include a nucleic acid programmable DNA binding protein and an adenosine methyltransferase domain. The base editors may be engineered through the use of continuous or non-continuous evolution systems, such as phage-assisted continuous evolution (PACE). In particular, the present disclosure provides for evolved adenine-to-thymine (or thymine-to-adenine) base editor variants that overcome deficiencies in the art for base editors that can install single-base A:T to T:A transversion mutations. In some embodiments, methods for targeted nucleic acid editing are provided. In some embodiments, pharmaceutical compositions comprising, and vectors and kits for the generation of, targeted base editors are provided.

Abstract: Compositions and methods involving anti-neoantigen antibodies and/or effector cells armed with anti-neoantigen antibodies are disclosed herein. Such compositions may also include immune checkpoint inhibitors and may be used, for example, in the treatment of cancers.

Abstract: The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO2?). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

Abstract: The invention provides novel and versatile classes of riboregulators, including inter alia activating and repressing riboregulators, switches, and trigger and sink RNA, and methods of their use for detecting RNAs in a sample such as a well and in modulating protein synthesis and expression.

Abstract: Sample collection tubes and methods of producing the same are provided. Contemplated collection tubes comprise a tube having a separator substance disposed therein. In some aspects, the separator substance preferably maintains a predetermined flowability during irradiation or heat sterilization, and can subsequently polymerize upon exposure to a UV light or other suitable source.

Abstract: The present disclosure concerns inhibitors of Norovirus protease that are suitable for use against any genotype of Norovirus, including at least GII.4 Norovirus proteases. In particular embodiments, specific compositions are encompassed, including their use for prevention or treatment of Norovirus infection in an individual.

Abstract: The method comprising providing a plurality of images of a scene captured by a plurality of image capturing devices (101); providing silhouette information of at least one object in the scene (102); generating a point cloud for the scene in 3D space using the plurality of images (103); extracting an object point cloud from the generated point cloud, the object point cloud being a point cloud associated with the at least one object in the scene (104); estimating a 3D shape volume of the at least one object from the silhouette information (105); and combining the object point cloud and the shape volume of the at least one object to generate a three-dimensional model (106). An apparatus for generating a 3D model, and a computer readable medium for generating the 3D model.

Abstract: Various embodiments of systems and methods for a thermogalvanic brick are disclosed.

Abstract: Provided herein are compounds, compositions, and methods of identifying compounds that neutralize the ability of the cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from agonizing CB1 signaling in peripheral tissues. Further provided herein are methods of treating a disorder associated with dysregulated or abnormal hepatic de novo lipogenesis and/or hepatic selective insulin resistance by inhibiting cannabinoid receptor type-1 (CB1) agonist 2-arachidonylglycerol (2-AG) in complex with its obligate binding partner adipocyte lipid binding protein (aP2) from binding and agonizing CB1.

Abstract: CRISPR/Cas Systems are provided where a tuned guide RNA is used to discriminate between two protospacer sequences of same length that differ by one nucleotide.

Abstract: Systems and methods obtain functional connectivity data in the whole brain to detect and predict brain disorders. This whole brain data is regionalized and then manipulated to derive functional connectivity data sets that can be used to show measured functional connectivity changes. This whole brain data may also be analyzed to determine changes in functional activity in both increased and decreased neural network connectivity. By identifying and then quantifying the functional connectivity differences between healthy and diseased subjects, a classification for individual subjects can be made.

Abstract: Performance issues in a service function chain having a plurality of resources and a plurality of network functions each having a network function queue are diagnosed. Each network function queue is monitored and queueing information for input packets for each of the plurality of network functions is dumped to a data store. Each resource that is under contention is identified as well as which of the network functions is a contender for the resources. A diagnosing algorithm is used to diagnose performance problems and an impact graph for each victim packet is generated. A summary of results as a list of rules is then provided.

Abstract: Motion data collected by a sensing device attached to a patient's arm may be used to determine whether the arm is subject to thoracic outlet syndrome (TOS) Motion data regarding motion of an arm of a patient may be received from a sensing device. One or more extremity performance parameters for the arm may be determined based, at least in part, on the motion data. A determination may be made based, at least in part, on the one or more extremity performance parameters whether the arm is subject to TOS.

Abstract: The presently disclosed invention relates to a method of diagnosing Multiple Sclerosis (MS) in a patient comprising obtaining a sample from the patient, determining a level of one or more H2S generating enzymes in the sample from the patient, and diagnosing the patient with MS when the level of the one or more H2S generating enzymes is one of at least 15% higher or lower than a control level for the one or more H2S generating enzymes, and at least 10% higher or lower than a control level for the one or more H2S generating enzymes.

Abstract: Aspects of the invention provide methods for harnessing the potential of proteins that occur naturally (e.g., in humans) and that have serious but finite toxicity. Aspects of the invention relate to a quantitative systems-biological and structural approach to design a class of chimeric proteins that avoid the toxicity of protein drugs while retaining their desired activities. In particular, chimeric proteins containing a variant form of a natural protein fused to a targeting moiety may be administered to a subject to target a signal (e.g., induction of apoptosis) to particular cells without having a generalized toxic effect in the subject.

Abstract: The present disclosure relates to a biocompatible composition comprising a solution of low molecular weight polymer and high molecular weight polymer. The present disclosure also relates to biocompatible compositions comprising poly(lactic-co-glycolic acid) (PLGA) and poly(ethylene glycol) (PEG), and additionally including a suspension of silica particles and/or a therapeutic agent. The present disclosure is also directed to biocompatible polymer fiber constructs formed from the disclosed compositions, methods of fabrication thereof, and uses of such constructs and compositions.

Abstract: The present disclosure provides, in some aspects, nucleic acid nanostructures covalently linked to oligolysine-PEG copolymers.

Abstract: The present invention provides novel peripherally-restricted benzodiazepines with reduced blood brain barrier permeability and methods of use thereof for reducing tactile dysfunction, social impairment, and anxiety in a subject diagnosed with Autism Spectrum Disorder, Rett syndrome, Phelan McDermid syndrome, or Fragile X syndrome.